Takeda has unveiled promising phase 3 data for its TYK2 inhibitor, zasocitinib, targeting moderate to severe plaque psoriasis, positioning itself against competitors like Bristol Myers Squibb (BMS) and Johnson & Johnson. The trials demonstrated significant efficacy, with over 61% of patients achieving a PASI 90 response at Week 16, compared to just 5% for placebo and 16.8% for apremilast (Otezla). Zasocitinib also showed notable PASI 100 rates, indicating clear skin, at 33.4% and 25.2%, further underscoring its therapeutic potential.

This data is crucial as it highlights the competitive landscape of psoriasis treatments, where efficacy and dosing convenience can significantly influence market share. Takeda’s forecast of $3 billion to $6 billion in peak revenue reflects strong confidence in zasocitinib’s market position, especially given the absence of a food effect and its once-daily dosing regimen, which may enhance patient adherence compared to other therapies.

As the field moves toward more effective treatments for psoriasis, the implications of zasocitinib’s performance could reshape treatment paradigms and influence future research directions in autoimmune therapies.

Source: fiercebiotech.com